Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands.
JAMA. 2016 Jul 19;316(3):300-12. doi: 10.1001/jama.2016.9389.
Previous studies of breast cancer risk after in vitro fertilization (IVF) treatment were inconclusive due to limited follow-up.
To assess long-term risk of breast cancer after ovarian stimulation for IVF.
DESIGN, SETTING, AND PARTICIPANTS: Historical cohort (OMEGA study) with complete follow-up through December 2013 for 96% of the cohort. The cohort included 19,158 women who started IVF treatment between 1983 and 1995 (IVF group) and 5950 women starting other fertility treatments between 1980 and 1995 (non-IVF group) from all 12 IVF clinics in the Netherlands. The median age at end of follow-up was 53.8 years for the IVF group and 55.3 years for the non-IVF group.
Information on ovarian stimulation for IVF, other fertility treatments, and potential confounders was collected from medical records and through mailed questionnaires.
Incidence of invasive and in situ breast cancers in women who underwent fertility treatments was obtained through linkage with the Netherlands Cancer Registry (1989-2013). Breast cancer risk in the IVF group was compared with risks in the general population (standardized incidence ratios [SIRs]) and the non-IVF group (hazard ratios [HRs]).
Among 25,108 women (mean age at baseline, 32.8 years; mean number of IVF cycles, 3.6), 839 cases of invasive breast cancer and 109 cases of in situ breast cancer occurred after a median follow-up of 21.1 years. Breast cancer risk in IVF-treated women was not significantly different from that in the general population (SIR, 1.01 [95% CI, 0.93-1.09]) and from the risk in the non-IVF group (HR, 1.01 [95% CI, 0.86-1.19]). The cumulative incidences of breast cancer at age 55 were 3.0% for the IVF group and 2.9% for the non-IVF group (P = .85). The SIR did not increase with longer time since treatment (≥20 years) in the IVF group (0.92 [95% CI, 0.73-1.15]) or in the non-IVF group (1.03 [95% CI, 0.82-1.29]). Risk was significantly lower for those who underwent 7 or more IVF cycles (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF cycles and after poor response to the first IVF cycle (HR, 0.77 [95% CI, 0.61-0.96] for <4 vs ≥4 collected oocytes).
Among women undergoing fertility treatment in the Netherlands between 1980 and 1995, IVF treatment compared with non-IVF treatment was not associated with increased risk of breast cancer after a median follow-up of 21 years. Breast cancer risk among IVF-treated women was also not significantly different from that in the general population. These findings are consistent with absence of a significant increase in long-term risk of breast cancer among IVF-treated women.
由于随访时间有限,之前关于体外受精 (IVF) 治疗后乳腺癌风险的研究结果尚无定论。
评估卵巢刺激后进行 IVF 治疗的长期乳腺癌风险。
设计、设置和参与者:这是一项具有完整随访的历史队列研究(OMEGA 研究),截至 2013 年 12 月,队列中有 96%的成员完成了随访。该队列包括 19158 名 1983 年至 1995 年期间接受 IVF 治疗的女性(IVF 组)和 5950 名 1980 年至 1995 年期间接受其他生育治疗的女性(非-IVF 组),来自荷兰所有 12 家 IVF 诊所。IVF 组的中位随访结束年龄为 53.8 岁,非-IVF 组为 55.3 岁。
从医疗记录和邮寄问卷中收集了关于 IVF 卵巢刺激、其他生育治疗和潜在混杂因素的信息。
通过与荷兰癌症登记处(1989-2013 年)的链接,获得了接受生育治疗的女性侵袭性和原位乳腺癌的发病率。将 IVF 组的乳腺癌风险与一般人群(标准化发病比 [SIR])和非-IVF 组(风险比 [HR])进行比较。
在 25108 名女性(基线平均年龄为 32.8 岁,平均 IVF 周期数为 3.6 个)中,中位随访 21.1 年后发生了 839 例侵袭性乳腺癌和 109 例原位乳腺癌。接受 IVF 治疗的女性乳腺癌风险与一般人群(SIR,1.01 [95%CI,0.93-1.09])和非-IVF 组(HR,1.01 [95%CI,0.86-1.19])无显著差异。在 55 岁时,IVF 组的累积乳腺癌发生率为 3.0%,非-IVF 组为 2.9%(P = .85)。IVF 组(0.92 [95%CI,0.73-1.15])或非-IVF 组(1.03 [95%CI,0.82-1.29])治疗时间≥20 年时,SIR 并未增加。与接受 1-2 个 IVF 周期相比,接受 7 个或更多 IVF 周期的患者风险显著降低(HR,0.55 [95%CI,0.39-0.77]),而首次 IVF 周期反应不佳的患者风险也显著降低(HR,0.77 [95%CI,0.61-0.96],<4 个 vs ≥4 个采集的卵母细胞)。
在 1980 年至 1995 年期间在荷兰接受生育治疗的女性中,与非-IVF 治疗相比,IVF 治疗后 21 年的中位随访时间乳腺癌风险并未增加。接受 IVF 治疗的女性的乳腺癌风险也与一般人群无显著差异。这些发现与 IVF 治疗女性中乳腺癌长期风险无显著增加一致。